IDEAYA Biosciences (NASDAQ:IDYA) Director Timothy M. Shannon bought 400,000 shares of the stock in a transaction on Tuesday, May 28th. The shares were acquired at an average cost of $10.00 per share, for a total transaction of $4,000,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of NASDAQ IDYA opened at $6.31 on Friday. The firm has a 50 day moving average price of $7.34. IDEAYA Biosciences has a 52 week low of $6.12 and a 52 week high of $16.90.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings results on Monday, August 12th. The company reported ($1.30) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.66). On average, research analysts expect that IDEAYA Biosciences will post -3.02 earnings per share for the current year.

Several research firms have weighed in on IDYA. Citigroup began coverage on IDEAYA Biosciences in a research note on Monday, June 17th. They set a “buy” rating and a $20.00 target price on the stock. JPMorgan Chase & Co. began coverage on IDEAYA Biosciences in a research note on Monday, June 17th. They set a “neutral” rating and a $15.00 target price on the stock. Finally, Jefferies Financial Group began coverage on IDEAYA Biosciences in a research note on Monday, June 17th. They set a “buy” rating and a $14.00 target price on the stock.

Several hedge funds and other institutional investors have recently made changes to their positions in IDYA. Perceptive Advisors LLC bought a new stake in shares of IDEAYA Biosciences in the 2nd quarter valued at approximately $11,369,000. Boxer Capital LLC bought a new stake in shares of IDEAYA Biosciences in the 2nd quarter valued at approximately $7,612,000. Point72 Asset Management L.P. bought a new stake in shares of IDEAYA Biosciences in the 2nd quarter valued at approximately $1,948,000. Victory Capital Management Inc. bought a new stake in shares of IDEAYA Biosciences in the 2nd quarter valued at approximately $1,453,000. Finally, Monashee Investment Management LLC bought a new stake in shares of IDEAYA Biosciences in the 2nd quarter valued at approximately $354,000. 0.62% of the stock is owned by institutional investors and hedge funds.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.

Read More: Bear Market – How and Why They Occur

Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.